![](https://investorshub.advfn.com/uicon/81806.png?cb=1635633872)
Wednesday, January 30, 2008 8:36:24 AM
Wednesday January 30, 8:30 am ET
SAN CARLOS, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO - News) today announced that it has enrolled the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172, a thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers.
"This proof-of-concept trial will allow us to quickly determine NU172's potential to achieve rapid onset and offset of anticoagulation," said Michael Levy, executive vice president of research and development for Nuvelo. "We look forward to sharing top-line data from this trial in the first half of 2008."
NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions. Data from early animal models suggest that NU172 has the potential for predictable anticoagulant effects, rapid onset and offset of action, and avoidance of heparin-induced thrombocytopenia.
About Aptamers
Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and affinity, and the ability to target protein-protein interactions.
http://biz.yahoo.com/prnews/080130/aqw051.html?.v=45
Recent ABIO News
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/15/2024 08:17:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:15:35 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/09/2024 12:35:20 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/01/2024 08:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:25:09 PM
- ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/01/2024 08:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/01/2024 08:10:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:05:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 02:50:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/25/2024 04:15:10 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/22/2024 09:17:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 11:38:10 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 11:10:32 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:29:01 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 07/09/2024 09:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 09:01:28 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/05/2024 09:20:16 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 06/18/2024 09:17:29 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/06/2024 08:45:16 PM
- Kuehn Law Encourages ABIO, SQSP, SSB, and HMNF Investors to Contact Law Firm • PR Newswire (US) • 05/22/2024 07:08:00 PM
- ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/25/2024 08:15:00 PM
- Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm • PR Newswire (US) • 04/05/2024 05:09:00 PM
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreement • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreement • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
FEATURED POET Technologies Reports Second Quarter 2024 Financial Results • Aug 15, 2024 8:04 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
ATWEC Reaches Profitability, Announces Massive Earnings Growth, and a Strong Forecast for the Rest of 2024 • ATWT • Aug 15, 2024 7:16 AM